From chemotherapy to oncoviruses – modern methods of treatment in metastatic melanoma

Hanna H. Drobek; Beata S. Bergler-Czop; Bartosz Miziołek

doi:10.5114/dr.2017.69947

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2017
vol. 104

Send email

Copy url:

abstract:

Review paper

From chemotherapy to oncoviruses – modern methods of treatment in metastatic melanoma

Hanna H. Drobek

,

Beata S. Bergler-Czop

,

Bartosz Miziołek

Dermatol Rev/Przegl Dermatol 2017, 104, 396-410

DOI: https://doi.org/10.5114/dr.2017.69947

Online publish date: 2017/09/15

View full text Get citation

PlumX metrics:

Melanoma develops from neuroectodermal cells known as melanocytes. Recent studies have revealed an alarming increase in the annual incidence of this disease in Poland and worldwide. Although melanoma accounts for a small percentage of occurrences in comparison with all cancers, it develops rapidly, proceeding in a short time to the advanced stage of the disease; thus successful therapy of melanoma becomes the key solution. The early treatment dates back to dacarbazine, a cytostatic drug, giving a clinical response only in approximately 15% of patients. However, targeted molecular treatment and immunotherapy have been essential breakthroughs, including BRAF inhibitors and ipilimumab, announced recently as the discovery of the decade. Furthermore, later medical studies have led to surprising findings, a crucial example being oncolytic therapy which attenuated viruses. Talimogene (T-VEC) is the first drug of this kind approved in unresectable melanoma. Research on its therapeutic properties is still ongoing.

keywords:

From chemotherapy to oncoviruses – modern methods of treatment in metastatic melanoma

Hanna H. Drobek , Beata S. Bergler-Czop , Bartosz Miziołek

melanoma, resistance, ipilimumab, BRAF inhibitors, talimogene

Hanna H. Drobek

,

Beata S. Bergler-Czop

,

Bartosz Miziołek